

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2020/165437 A1

(43) International Publication Date
20 August 2020 (20.08.2020)

(51) International Patent Classification:

C07K 16/28 (2006.01) G01N 33/53 (2006.01)

(21) International Application Number:

PCT/EP2020/053962

(22) International Filing Date:

14 February 2020 (14.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/806,002 15 February 2019 (15.02.2019) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).

(72) Inventors: **CASEY, Kerry**; MedImmune, LLC One
MedImmune Way, Gaithersburg, Maryland 20878 (US).
SINIBALDI, Dominic; MedImmune, LLC One MedImmune
Way, Gaithersburg, Maryland 20878 (US). **SMITH,
Michael**; MedImmune, LLC One MedImmune Way,
Gaithersburg, Maryland 20878 (US). **SANJUAN, Miguel**;
MedImmune, LLC One MedImmune Way, Gaithersburg,
Maryland 20878 (US).

(74) Agent: **HUGHES, Rosemary**; AstraZeneca Intellectual
Property, Milstein Building, Granta Park, Cambridge Cam-
bridgeshire CB21 6GH (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: TYPE I INTERFERON-MEDIATED DISORDERS

(57) Abstract: The invention provides methods of identifying, diagnosing, treating, and monitoring or prognosing progression of type I IFN-mediated disease or disorder in subjects. The present invention further relates to methods of identifying candidate therapeutic agents for treating a type I interferon-mediated disease or disorder.

WO 2020/165437 A1